Cite
HARVARD Citation
Lewis, J. et al. (n.d.). S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn's Disease: PROMIS-29 in the SEAVUE Study. American journal of gastroenterology. p. S395. [Online].